Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Orchid Chemicals and Pharmaceuticals — Investor Presentation (February 2012)
15 slides from Orchid Pharma's investor presentation, February 2012
Slide 1: Corporate Presentation
February 2012 Corporate Presentation www.orchidpharma.com
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Orchid Chemicals and Pharmaceuticals Limited (“Orchid” or the “Company”) solely for your information and for your use and may not be taken away, distributed, reproduced, or redistributed or passed on, directly or indirectly, to any other person (whet
Slide 3: Business Snapshot
Business Snapshot One of the leading Indian Specialty companies with strong capabilities in oral and injectable antibiotic APIs and niche generics Business Overview Consolidated Financials(1) Promoted by K. Raghavendra Rao, who has been conferred the Padma Shri in 2011 by the Government of India 9
Slide 4: Attractive and Large Market Opportunity
Attractive and Large Market Opportunity Overview Generics Market Expected to Grow Significantly… Global generics market is expected to grow to US$ 135- 150bn in 2015 owing to the impending patent cliff, increasing $135-$150 penetration of generics and higher consumption The generics injectables
Slide 5: Business Highlights
Business Highlights 1 A High End Specialty Player 2 Integrated Capabilities 3 Diversified Geographic Presence Product portfolio of niche molecules involving Strong end-to-end capabilities with presence Orchid has global presence in over 70 complex chemistry, multi-step manufacturing, across th
Slide 6: A High End Specialty Player
1 A High End Specialty Player Key Business Segments Orchid Chemicals & Pharmaceuticals Limited NPNC (Non-penicillin and Cephalosporin Penicillin Carbapenems Non-cephalosporin) API for Injectables API for Injectables API for Injectables API for Orals API for Orals Orals (FDFs) Orals (FDFs) Product Of
Slide 7: Integrated Capabilities
2 Integrated Capabilities Orchid is present across the value chain Front end presence across Partnerships geographies FDFs across APIs for multiple therapeutic areas dosage forms R&D / Regulatory Capability End-to-end development capabilities delivers higher margins Strong R&D capability with a te
Slide 8: Diversified Geographic Presence
3 Diversified Geographic Presence Orchid has a global presence across 70+ countries through alliances, joint ventures and partnerships Worldwide revenues (FY11, US$ mm) API FDF 287 76 Emerging Markets revenues EU revenues (FY11, US$ mm) (FY11, US$ mm) API FDF API FDF 117 13 66 3 US revenues (FY11, U
Slide 9: Strong Manufacturing Infrastructure
4 Strong Manufacturing Infrastructure Capacity expansion based on order-book of top clients and strong FDF pipeline Facility Products Approvals Markets API Facility Penicillins, Sterile Carbapenems, UK MHRA, US FDA, OHSAS 18001: 1999, Emerging and Aurangabad, Non-Penicillin, Non-cephalosporins Danis
Slide 10: Excellent Regulatory & R&D Capabilities
5 Excellent Regulatory & R&D Capabilities Overview of Regulatory Capabilities Finished Dosage Forms: Regulatory Status Strong track record of regulatory filings By Geography By Product Segment – An aggregate of 68 filings across NPNC and Cephalosporins in regulated markets (43 ANDAs in 43 42 the U
Slide 11: NCE Pipeline
6 NCE Pipeline Orchid has an NCE pipeline with drugs for a multitude of therapeutic areas in various stages of development Follows one of the following business models – Out-licensing of NCEs (early phase or proof-of-concept phase) – Co-development of NCEs – „FTE‟ based or „Fee for Service‟ base
Slide 12: Strong Operating Performance
7 Strong Operating Performance Total Operating Income (1) (4) Key Highlights Post-Hospira Transaction FY2009 FY2010 FY2011 FY2012 Revenue growth of 33% in FY11 driven by: 33% – API supplies to Hospira 363 110 97 101 – Tazobactam – Piperacillin 288 91 95 (US$ in Millions) 265 264 274 254 – Meropene
Slide 13: Improved Financial Position
7 Improved Financial Position Debt Break up (1) (2) Net Debt / Equity (2) Pre-Hospira Deal Post-Hospira Deal Pre-Hospira Deal Post-Hospira Deal 700 5.0 600 547 4.0 (US$ in Millions) 500 4.0 417 176 388 400 346 2.9 174 22 3.0 300 117 (x) 135 200 43 349 2.0 1.5 271 1.4 100 200 211 0 1.0 2008 2009 2010
Slide 14: Strategy in Place To Achieve Next Growth Phase
8 Strategy in Place To Achieve Next Growth Phase Focus on long term supply contracts, new product approvals and development of new product segments to be the key growth drivers in the short –medium term Clear defined strategies for API / Oral FDF / CRAMS segment Focus on long term contracts with
Slide 15: Thank You
THANK YOU For any information or clarifications, please visit www.orchidpharma.com or call Ch Ram, Head - Communication & Investor Relations on +91 98400 11626 / [email protected] © 2012 Orchid Chemicals & Pharmaceuticals Ltd., All Rights Reserved. This material was used during an oral presentati
Orchid Chemicals and Pharmaceuticals — Investor Presentation (February 2012) on 6ix